Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety

Efalizumab is a humanized monoclonal antibody directed against the CD11a subunit of the lymphocyte function-associated antigen 1. It has been approved for the treatment of moderate-to-severe plaque psoriasis. Efalizumab has been shown in several clinical